Azurity Pharmaceuticals' Class I Dextroamphetamine Sulfate Recall Highlights Critical Labeling Risks
Azurity Pharmaceuticals initiated a Class I recall for 4,662 bottles of Zenzedi (Dextroamphetamine Sulfate) CII Tablets due to a labeling mix-up. This high-severity event, now terminated, underscores critical quality control deficiencies in pharmaceutical packaging. Procurement, regulatory, and supply chain leaders must enhance due diligence on contract manufacturers and internal labeling processes to mitigate similar risks with controlled substances.
FDA Class I Action: Azurity Pharmaceuticals' Critical Labeling Mix-up for Dextroamphetamine Sulfate
Azurity Pharmaceuticals, Inc., based in Wilmington, MA, initiated a voluntary Class I recall (D-0323-2024) on January 4, 2024, for 4,662 bottles of Zenzedi (Dextroamphetamine Sulfate) CII Tablets, USP, 30 mg. The affected product, specifically lot number F230169A with an expiration date of June 30, 2025, was distributed nationwide across the USA. The critical reason for this recall was identified as a labeling mix-up, a fundamental failure in quality control that carries severe implications for patient safety. This Class I classification, the most severe issued by the FDA, signifies a reasonable probability that using or being exposed to the mislabeled product could lead to serious adverse health consequences or even death. For procurement directors, this mandates an immediate audit of all inventory, particularly lot F230169A, to ensure no mislabeled product remains in the supply chain. Regulatory affairs heads must scrutinize internal labeling and packaging protocols, identifying potential vulnerabilities that could lead to such a critical error, especially with controlled substances. Supply chain VPs face the immediate operational challenge of managing reverse logistics for the 4,662 affected bottles and assessing any potential downstream impact on patient access, despite the recall's termination on September 18, 2024.
Operational Footprint and Contract Manufacturing Implications for Azurity Pharmaceuticals
Azurity Pharmaceuticals, Inc. operates from Wilmington, MA, and is responsible for manufacturing Zenzedi, a Dextroamphetamine Sulfate formulation. This molecule is classified as a Schedule II controlled substance, a designation that mandates extremely stringent manufacturing, labeling, and distribution controls due to its high potential for abuse and dependence. The recall highlights that even products under the highest regulatory scrutiny can be subject to critical errors in the manufacturing process. Notably, the recalled product was manufactured for Arbor Pharmaceuticals, LLC, based in Atlanta, Georgia. This detail points to a contract manufacturing relationship, where Azurity Pharmaceuticals serves as a contract development and manufacturing organization (CDMO) for Arbor. For business development executives, this recall raises critical questions about the robustness of quality agreements, oversight mechanisms, and audit processes in contract manufacturing partnerships. Companies relying on Azurity for similar products, or those considering them as a CDMO, must conduct enhanced due diligence on their labeling and quality control systems. Procurement directors sourcing Dextroamphetamine Sulfate or similar controlled substances should review their supplier qualification processes, especially concerning labeling accuracy and quality assurance at third-party manufacturers.
Broader Supply Chain Vulnerabilities and Regulatory Compliance Trends
The nationwide distribution of 4,662 bottles of a Class I recalled controlled substance like Dextroamphetamine Sulfate underscores potential localized supply chain vulnerabilities. While Azurity Pharmaceuticals' recall has been terminated as of September 18, 2024, indicating the immediate market risk has been addressed, the event itself highlights the fragility of pharmaceutical supply chains when critical errors occur. Such incidents can lead to temporary shortages, impact patient care, and erode trust in the supply chain. This incident is not isolated within the broader regulatory landscape. ChemLifeIntel's intelligence indicates a pattern of significant recalls across the industry. Recent Class I recalls include Pfizer's Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter. Furthermore, Class II actions have impacted Sandoz's Enoxaparin Sodium and Teva's Warfarin Sodium, often linked to CGMP deviations or storage issues. These parallel events, while distinct in their root causes, collectively emphasize systemic pressures on quality control. Supply chain VPs must prioritize supplier diversification and robust risk management strategies, particularly for critical and controlled substances. The frequency of such events, even from major players, mandates a proactive approach to auditing and monitoring contract manufacturers and distributors.
Remediation, Compliance Expectations, and Future Market Reassurance
Azurity Pharmaceuticals' firm-initiated recall (D-0323-2024) for Zenzedi (Dextroamphetamine Sulfate) was terminated on September 18, 2024, signifying that the immediate market risk has been addressed and the FDA has accepted the company's corrective actions. However, a Class I classification for a labeling mix-up points to a critical lapse in Good Manufacturing Practices (GMP) within Azurity's quality management system. While specific details of the mix-up are not publicly disclosed, such errors typically stem from inadequate line clearance procedures, insufficient in-process controls, or human error during packaging operations. For regulatory affairs teams at other pharmaceutical companies, this event serves as a crucial case study to reinforce training and procedural controls around labeling and packaging, especially for high-risk products like controlled substances. Business development executives considering partnerships with Azurity or other manufacturers must scrutinize their quality audit reports, specifically looking for evidence of robust labeling verification processes and a strong culture of quality. Procurement directors should ensure their supplier agreements include stringent clauses on quality control, recall procedures, and transparency regarding root cause analysis, thereby safeguarding their supply chains against similar high-impact regulatory actions.